Adverse Prognostic Significance of Activation‐Induced Cytidine Deaminase in Diffuse Large B‐Cell Lymphoma Patients Treated With R‐ CHOP
Cancer Reports · 2026-05 · 9 (5)
DOI: 10.1002/cnr2.70557 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Reports, online erschienen am 28.04.2026. Verfasst von Mardiah Suci Hardianti und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Medical-Oncology, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada…. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Antineoplastic Combined Chemotherapy Protocols, Cytidine Deaminase, Biomarkers, Tumor. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PDUPT Grant of Indonesian Ministry of Research and Technology/National Agency for Research and Innovation 2020, Kementerian Pendidikan, Kebudayaan, Riset, dan Teknologi.
Abstract (Originalsprache)
Background
A number of studies have demonstrated the important role of activation‐induced cytidine deaminase (AID) in the pathogenesis of diffuse large B‐cell lymphoma (DLBCL). AID has been relatively underexplored as a prognostic factor in DLBCL, and its role remains controversial.
Aims
This study conducted a comprehensive analysis of the association between AID expression and clinical outcomes in 70 Indonesian patients with DLBCL treated with a standard CHOP ± rituximab regimen. Methods and Results Immunostaining results showed that AID was expressed in 35.7% of DLBCL samples. Multivariate analysis indicated that positive AID expression was associated with shorter overall survival (OS) specifically among patients receiving a rituximab‐containing regimen, with a hazard ratio of 10.39 (95% CI: 1.93–55.96; p = 0.006).
Conclusion
The significant prognostic value of AID in the DLBCL subgroup treated with rituximab—but not in the general DLBCL population or in those not receiving rituximab—underscores the potential relevance of AID expression in DLBCL management and treatment decisions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology and Medical-Oncology, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital, Yogyakarta, Indonesia.
- Department of Anatomical Pathology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital, Yogyakarta, Indonesia.
ORCID-Profile: Mardiah Suci Hardianti, Nungki Anggorowati, Syahru Agung Setiawan, Miraz Radhea Bagaskoro, Johan Kurnianda, Kartika Widayati Taroeno-Hariadi, Ibnu Purwanto, Susanna Hilda Hutajulu
Förderung
- PDUPT Grant of Indonesian Ministry of Research and Technology/National Agency for Research and Innovation 2020
- Kementerian Pendidikan, Kebudayaan, Riset, dan Teknologi
Zitieren
APA
Hardianti, M. S., Anggorowati, N., Setiawan, S. A., Bagaskoro, M. R., Kurnianda, J., Taroeno-Hariadi, K. W., Purwanto, I., & Hutajulu, S. H. (2026). Adverse Prognostic Significance of Activation‐Induced Cytidine Deaminase in Diffuse Large B‐Cell Lymphoma Patients Treated With R‐ CHOP. Cancer Reports, 9(5). https://doi.org/10.1002/cnr2.70557
Vancouver
Hardianti MS, Anggorowati N, Setiawan SA, Bagaskoro MR, Kurnianda J, Taroeno-Hariadi KW, et al. Adverse Prognostic Significance of Activation‐Induced Cytidine Deaminase in Diffuse Large B‐Cell Lymphoma Patients Treated With R‐ CHOP. Cancer Reports. 2026;9(5). doi:10.1002/cnr2.70557
BibTeX
@article{Hardianti2026,
author = {Hardianti, Mardiah Suci and Anggorowati, Nungki and Setiawan, Syahru Agung and Bagaskoro, Miraz Radhea and Kurnianda, Johan and Taroeno-Hariadi, Kartika Widayati and Purwanto, Ibnu and Hutajulu, Susanna Hilda},
title = {Adverse Prognostic Significance of Activation‐Induced Cytidine Deaminase in Diffuse Large B‐Cell Lymphoma Patients Treated With R‐ CHOP},
journal = {Cancer Reports},
year = {2026},
volume = {9},
number = {5},
doi = {10.1002/cnr2.70557}
}
EUVIMED